The Alzheimer’s disease drug development pipeline 2025 is evolving rapidly, with innovative therapies targeting multiple disease mechanisms. While past treatments primarily addressed amyloid-beta plaques, recent research has expanded to include tau-targeting therapies, neuroinflammation inhibitors, and synaptic function enhancers. With drugs like Leqembi (lecanemab) now on the market, new...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek